Media headlines about Collegium Pharmaceutical (NASDAQ:COLL) have trended somewhat positive recently, according to Accern. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Collegium Pharmaceutical earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 45.3118094909066 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:
- Head to Head Analysis: Collegium Pharmaceutical (COLL) versus Versartis (VSAR) (americanbankingnews.com)
- Collegium Pharmaceutical Inc (COLL) Insider Sells $110,592.00 in Stock (americanbankingnews.com)
- Collegium Pharmaceutical Inc (COLL) Chairman Michael Thomas Heffernan Sells 150,000 Shares (americanbankingnews.com)
- Cantor Fitzgerald Out Bullish On Collegium As ‘Leading Company’ In Pain Management (benzinga.com)
- Collegium Pharmaceutical (COLL) Coverage Initiated at Cantor Fitzgerald (americanbankingnews.com)
A number of research firms have recently weighed in on COLL. BidaskClub raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Monday, May 14th. HC Wainwright increased their price objective on Collegium Pharmaceutical from $21.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, March 8th. Zacks Investment Research lowered Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Tuesday, May 15th. ValuEngine raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Finally, William Blair reissued an “outperform” rating on shares of Collegium Pharmaceutical in a research note on Thursday, March 8th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $32.14.
Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Wednesday, May 9th. The specialty pharmaceutical company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.02). Collegium Pharmaceutical had a negative return on equity of 72.87% and a negative net margin of 78.22%. The business had revenue of $63.70 million during the quarter, compared to analysts’ expectations of $51.92 million. During the same period in the previous year, the business earned ($0.79) EPS. The business’s revenue was up 2835.5% compared to the same quarter last year. research analysts predict that Collegium Pharmaceutical will post -1.23 EPS for the current year.
In related news, insider Alison B. Fleming sold 4,096 shares of the firm’s stock in a transaction on Tuesday, June 12th. The stock was sold at an average price of $27.00, for a total value of $110,592.00. Following the completion of the sale, the insider now owns 53,362 shares of the company’s stock, valued at $1,440,774. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Michael Thomas Heffernan sold 44,400 shares of the firm’s stock in a transaction on Thursday, April 19th. The stock was sold at an average price of $26.00, for a total value of $1,154,400.00. Following the completion of the sale, the chairman now directly owns 545,893 shares of the company’s stock, valued at approximately $14,193,218. The disclosure for this sale can be found here. Insiders sold 278,179 shares of company stock valued at $6,855,531 in the last ninety days. 25.76% of the stock is currently owned by insiders.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.